SCHEMBL322192

SCHEMBL322192

CCC(=O)N1CCC(O)C1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.51
CHRNB2 P17787 3/20 0.47
CHRNA3 P32297 3/20 0.47
CHRNA4 P43681 3/20 0.47
CHRNB3 Q05901 1/20 0.47
CHRNA6 Q15825 1/20 0.47
EPHX2 P34913 5/20 0.46
CHRNB4 P30926 2/20 0.46
CHRNA7 P36544 2/20 0.46
ALDH1A1 P00352 2/20 0.44
DPP7 Q9UHL4 2/20 0.44
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM1 P11229 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
EPHX1 P07099 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL322191 1.00 DPP4 (0.51) DPP4CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL10272430 1.00 DPP4 (0.51) DPP4CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL10305072 0.88 MEN1 (0.47) DPP4CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL10305071 0.88 MEN1 (0.47) DPP4CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL13612864 0.88 MEN1 (0.47) DPP4CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL20927239 0.88 DPP4 (0.47) DPP4CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL7487836 0.87 EPHX2 (0.53) DPP4CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL9221110 0.84 CHRNB2 (0.50) DPP4CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL11892683 0.84 CHRNB2 (0.50) DPP4CHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL9216541 0.84 CHRNB2 (0.50) DPP4CHRNB2CHRNA3CHRNA4CHRNB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020011243-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF BETTA PHARMACEUTICALS CO., LTD (CN) 2020-01-16 WO claimed
US-20250257035-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2025-08-14 US disclosed
US-20250059181-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives NOVARTIS AG (CH) 2025-02-20 US disclosed
US-12098130-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2024-09-24 US disclosed
US-20230391723-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2023-12-07 US disclosed
US-11718628-B2 SREBP inhibitors comprising a 6-membered central ring CAPULUS THERAPEUTICS, LLC (US) 2023-08-08 US disclosed
US-11702388-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2023-07-18 US disclosed
WO-2023109883-A1 AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2023-06-22 WO disclosed
WO-2023093832-A1 TRICYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海济煜医药科技有限公司 2023-06-01 WO disclosed
WO-2022271562-A1 HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2022-12-29 WO disclosed
US-7638523-B2 Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors IRM LLC (BM) 2009-12-29 US disclosed
US-20090264649-A1 DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS IRM LLC (BM) 2009-10-22 US disclosed
WO-2009115547-A1 TRISUBSTITUTED 1, 2, 4 -TRIAZOIIES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2009-09-24 WO disclosed
US-20090192138-A1 COMPOUNDS BAESCHLIN DANIEL KASPAR 2009-07-30 US disclosed
US-20090012094-A1 DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) 2009-01-08 US disclosed
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF METHLYGENE INC. (CA) 2008-10-16 US disclosed
US-20080045516-A1 Viral Polymerase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-21 US disclosed
US-20070149538-A1 Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors IRM LLC (BM) 2007-06-28 US disclosed
WO-2007071738-A1 CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS NOVARTIS AG (CH) 2007-06-28 WO disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257035-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A DPP4 881/4885CHRNB2 4624/4885CHRNA3 4327/4885
US-11718628-B2 SREBP inhibitors comprising a 6-membered central ring SREBF1, SREBF2, XBP1 DPP4 2352/4885CHRNB2 4658/4885CHRNA3 4612/4885
US-20230391723-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A DPP4 881/4885CHRNB2 4624/4885CHRNA3 4327/4885
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 DPP4 1951/4885CHRNB2 4505/4885CHRNA3 4315/4885
US-20090012094-A1 DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS KIT, PRKCH, PRKCE DPP4 1263/4885CHRNB2 254/4885CHRNA3 195/4885
US-20090264649-A1 DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS KIT, PRKCH, PRKCE DPP4 1263/4885CHRNB2 254/4885CHRNA3 195/4885
US-20080255155-A1 KINASE INHIBITORS AND USES THEREOF ABL1, MAP3K20, MAP3K1 DPP4 1678/4885CHRNB2 4813/4885CHRNA3 4861/4885
US-20090192138-A1 COMPOUNDS DPP4, DPP3, DPP8 DPP4 1/4885CHRNB2 2257/4885CHRNA3 1223/4885
US-20250059181-A1 Tetrahydro-Pyrido-Pyrimidine Derivatives PIK3CA, TYMP, TYMS DPP4 1996/4885CHRNB2 2797/4885CHRNA3 2789/4885
US-11702388-B2 1,4-substituted piperidine derivatives FASN, CES1, CPT1A DPP4 881/4885CHRNB2 4624/4885CHRNA3 4327/4885
US-12098130-B2 1,4-substituted piperidine derivatives FASN, CES1, CPT1A DPP4 881/4885CHRNB2 4624/4885CHRNA3 4327/4885
US-20070149538-A1 Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors KIT, PRKCH, PRKCE DPP4 1263/4885CHRNB2 254/4885CHRNA3 195/4885
US-20080045516-A1 Viral Polymerase Inhibitors POLR2A, POLR2H, POLR2E DPP4 1629/4885CHRNB2 4762/4885CHRNA3 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.